MedPath

Paroxetine

Generic Name
Paroxetine
Brand Names
Paxil, Pexeva
Drug Type
Small Molecule
Chemical Formula
C19H20FNO3
CAS Number
61869-08-7
Unique Ingredient Identifier
41VRH5220H
Background

Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham. A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.

Indication

Paroxetine is indicated for the management of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder. One form of paroxetine, commercially known as Brisdelle, is used to manage mild to moderate vasomotor symptoms of menopause. Off-label, paroxetine may be used for the treatment of premature ejaculation or irritable bowel syndrome (IBS).

Associated Conditions
Generalized Anxiety Disorder, Irritable Bowel Syndrome (IBS), Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD), Vasomotor Symptoms Associated With Menopause

Interpersonal Psychotherapy for Treatment Resistant Depression

First Posted Date
2013-07-11
Last Posted Date
2013-07-11
Lead Sponsor
Hospital de Clinicas de Porto Alegre
Target Recruit Count
74
Registration Number
NCT01896349
Locations
🇧🇷

Federal University of Rio Grande do Sul / Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil

Interaction Between Paroxetine and Telaprevir

Phase 2
Terminated
Conditions
Hepatitis C Infection
Depression
Interventions
First Posted Date
2013-04-26
Last Posted Date
2020-12-08
Lead Sponsor
Radboud University Medical Center
Target Recruit Count
3
Registration Number
NCT01841502
Locations
🇳🇱

Academic Medical Centre Amsterdam, Amsterdam, Netherlands

🇳🇱

Reinier de Graaf Groep, Delft, Netherlands

🇳🇱

University Medical Centre Groningen, Groningen, Netherlands

and more 4 locations

Algorithm Guided Treatment Strategies for Major Depressive Disorder

Phase 4
Conditions
Major Depressive Disorder
Interventions
First Posted Date
2013-01-10
Last Posted Date
2013-01-10
Lead Sponsor
Shanghai Mental Health Center
Target Recruit Count
1080
Registration Number
NCT01764867
Locations
🇨🇳

Shanghai Mental Health Center, Shanghai, China

Paroxetine/Bupropion in Depression With Suicide Attempt or Thoughts: fMRI Study

Phase 4
Completed
Conditions
Depression
Suicidal Ideation
Interventions
First Posted Date
2012-12-13
Last Posted Date
2017-11-21
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
15
Registration Number
NCT01748955
Locations
🇺🇸

Columbia University/New York State Psychiatric Institute, New York, New York, United States

Neural Circuits in Women With Abuse and Posttraumatic Stress Disorder

Phase 4
Completed
Conditions
PTSD
Interventions
Drug: Placebo
Other: Positron Emission Tomography (PET) Imaging
First Posted Date
2012-09-10
Last Posted Date
2017-06-28
Lead Sponsor
Emory University
Target Recruit Count
91
Registration Number
NCT01681849
Locations
🇺🇸

Emory University, Atlanta, Georgia, United States

Type II Diabetes Mellitus in Patients Exposed to Pravastatin and Paroxetine

First Posted Date
2012-05-21
Last Posted Date
2014-07-02
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
1
Registration Number
NCT01602913

Effectiveness Study of Mirtazapine Combined With Paroxetine in Major Depressive Patients Without Early Improvement

Phase 4
Completed
Conditions
Major Depression
Interventions
First Posted Date
2011-10-25
Last Posted Date
2017-08-31
Lead Sponsor
Capital Medical University
Target Recruit Count
525
Registration Number
NCT01458626
Locations
🇨🇳

Beijing Anding Hospital, Beijing, Beijing, China

Lithium Versus Paroxetine in Major Depression

Phase 4
Completed
Conditions
Major Depressive Disorder
Interventions
First Posted Date
2011-08-12
Last Posted Date
2020-07-16
Lead Sponsor
Nova Scotia Health Authority
Target Recruit Count
2
Registration Number
NCT01416220
Locations
🇨🇦

Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada

Special Drug Use Investigation for PAXIL (Paroxetine) Social Anxiety Disorder (Long-term)

Completed
Conditions
Social Phobia
Interventions
First Posted Date
2011-06-20
Last Posted Date
2014-07-02
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
600
Registration Number
NCT01376271

Special Drug Use Investigation for PAXIL Tablet (Pediatric Panic Disorder)

Completed
Conditions
Panic Disorder
Interventions
First Posted Date
2011-06-20
Last Posted Date
2017-05-22
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
96
Registration Number
NCT01376128
© Copyright 2025. All Rights Reserved by MedPath